Year
2023
Summary
This research focuses on developing reliable blood-based biomarkers to evaluate new treatments for hereditary frontotemporal dementia. By identifying an imbalance between two key molecules, progranulin and prosaposin, the work aims to provide accurate measures of treatment effectiveness and bring hope to families carrying this devastating genetic condition